Pain Management Treatment Market to Catapult by 2018

Tuesday 16 April 2013, Amsterdam

This newly published “Pain Management Treatment Markets” report that the pain management treatment market will catapult by 2018.
    
Pain management drugs, or analgesics, can be categorized into three main modalities: acetaminophen, NSAIDs and opioids. Pain, meanwhile, can be categorized into four main modalities: acute, chronic, neuropathic and nociceptive. The pain management market is currently valued at $52 billion. Growing at a rate of 20%, the opioid segment will constitute a full 43% of the pain management market by 2018. Although the U.S. market will only increase modestly to $21.8 billion, it remains the largest market by far throughout the forecast period.
 
The “Pain Management Treatment Markets” report covers:

• CGRP antagonists
• CB2 agonists
• Sodium channel modulators
• Calcium channel modulators
• NMDA antagonists
• P2x receptors
• Trp channels
• TrpV1 blockers
• FAAH inhibitors
• Novel opioids
• Extended release formulations
• Transdermal formulations   
  

The “Pain Management Treatment Markets” report examines companies manufacturing pain management equipment and supplies in the world.

Companies covered include:

• Abbott,
• AcelRx,
• Acura,
• Afferent,
• Algiax,
• Arcion,
• Astellas,
• BioDelivery Sciences,
• Cara,
• Cephalon,
• Convergence,
• Cytogel,
• DURECT,
• Egalet,
• Eli Lilly,
• Endo,
• Grünenthal,
• Hospira,
• iMed,
• Johnson & Johnson,
• KemPharm,
• Mallinckrodt,
• NeurAxon,
• NeurogesX,
• Newron,
• Novartis,
• Nuvo,
• Pacira,
• Pain Therapeutics,
• Pfizer,
• Purdue,
• QRx,
• Relevare,
• Relmada,
• Spinifex,
• Xenon,
• Xenoport, Z
• alicus and Zogenix.